PDCD1 and neoplasm: Studies have shown that blocking the PD-L1–PD-1 signaling pathway, in conjunction with other immune therapies, prevents tumor progression by enhancing antitumor CTL activity and killing the tumor cells, and have demonstrated safety [83,145].